Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter Study

NCT05575830 is registered in ClinicalTrials.gov with Calmy Alexandra as lead sponsor.

NCT NCT05575830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05575830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Response to the Recombinant Zoster Vaccine in People Living With HIV Over 50 Years of Age Compared to Non-HIV Age- and Gender-matched Controls - The Shingr'HIV Phase IV Multicenter Study
Lead sponsor
Calmy Alexandra
Phase
Phase 4
Overall status
Active, not recruiting
Start date
December 14, 2022
Completion date
March 31, 2026
Enrollment
225 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rzv vaccine (shingrix ®)